China’s biosimilar market is expected to usher in a major breakthrough, following the launch of the first large scale collaborative partnership for biosimilars development between Amgen Inc. and Simcere Pharmaceutical Group on Oct. 12, which could potentially help China to explore the regulatory framework and pathway to review and accelerate biosimilar approvals.
The kick-off ceremony came after the late September announcement that the two companies would work together on four biosimilars from Amgen’s pipeline in the areas of inflammation and oncology. Disclosed at the ceremony, the drugs under collaboration include Amgevita (adalimumab-atto), a biosimilar to AbbVie Inc